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Objectives The goal of this study was to compare the performance of several measures of carotid intima-media thickness
(C-IMT) as predictors of cardiovascular events (CVEs), and to investigate whether they add to the predictive accu-
racy of Framingham risk factors (FRFs).
Background Various markers of subclinical atherosclerosis have been identified as predictors of CVEs, but the most powerful
variable is still under debate.
Methods A cohort study was carried out in 5 European countries. A total of 3,703 subjects (median age 64.4 years; 48%
men) were followed-up for a median of 36.2 months, and 215 suffered a first CVE (incidence: 19.9/1,000
person-years).
Results All measures of C-IMT and the interadventitia common carotid artery diameter (ICCAD) were associated with the
risk of CVEs, after adjustment for FRFs and therapies (all p  0.005). The average of 8 maximal IMT measure-
ments (IMTmean-max), alone or combined with ICCAD, classified events and non-events better than the common
carotid mean IMT (net reclassification improvement [NRI]: 11.6% and 19.9%, respectively; both p  0.01).
Compared with classification based on FRFs alone, the NRI resulting from the combination of FRFsICCADIMTmean-max
was 12.1% (p  0.01). The presence of at least 1 plaque (maximum IMT 1.5 mm) performed significantly
worse than composite IMTs that incorporated plaques (p  0.001). Adjusted Kaplan-Meier curves showed that
individuals with a FRS  22.6% (cohort average), and both IMTmean-max and ICCAD above the median, had a
6.5% risk to develop a CVE over 3 years versus a 3.4% risk for those with the same FRS, and both IMTmean-max
and ICCAD below the median.
Conclusions A risk stratification strategy based on C-IMT and ICCAD as an adjunct to FRFs is a rational approach to preven-
tion of cardiovascular disease. (J Am Coll Cardiol 2012;60:1489–99) © 2012 by the American College of Car-
diology Foundation
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vention is usually based on vas-
cular risk factors (VRFs), but the
current ability to predict new car-
diovascular events (CVEs) remains
limited, even using the “global risk
assessment approach” (1). Carotid
artery intima-media thickness (C-
IMT), measured by B-mode ultra-
sound, is a recognized marker of
carotid and coronary atherosclero-
sis (2), although it is still debated
whether C-IMT improves the
predictive capacity of VRFs (3–11).
See page 1500
Other uncertainties include iden-
tification of the most informative
segment (common carotid, bifur-
cation, or internal carotid arteries)
and/or the best summary measure
(mean, max, or mean–max).
Interadventitia common ca-
rotid artery diameter (ICCAD),
assessed in plaque-free areas, is another variable easily
measurable by B-mode ultrasound. ICCAD increases dur-
ing atherogenesis (12), and this enlargement is associated
with VRFs (13) and subclinical atherosclerosis (14,15). On
the basis of these premises, it can be hypothesized that, like
C-IMT, ICCAD may improve risk assessment in asymp-
tomatic individuals. Studies specifically designed to assess
the prognostic value of ICCAD are few (9,16–18). To the
best of our knowledge, only 1 study measured the predictive
capacity of the combination of C-IMT and ICCAD (9).
All the aforementioned issues have been addressed
in IMPROVE (Carotid Intima Media Thickness [IMT]
and IMT-Progression as Predictors of Vascular Events in a
High Risk European Population), a cohort study carried out
in 5 European countries (19). We performed a systematic
analysis to compare the performance of 11 different C-IMT
variables measured at baseline, as predictors of subsequent
CVEs. In addition, we investigated: 1) whether ICCAD is
a predictor of future CVEs independently of C-IMT; and
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Abbreviations
and Acronyms
CI  confidence interval
C-IMT  carotid artery
intima-media thickness
CVE  cardiovascular
event
FRF  Framingham risk
factor
FRS  Framingham risk
score
HR  hazard ratio
ICCAD  interadventitia
common carotid artery
diameter
IDI  integrated
discrimination improvement
IMT  intima-media
thickness
NRI  net reclassification
improvement
ROC  receiver-operating
characteristic
VRF  vascular risk factord
Manuscript received December 12, 2011; revised manuscript received June 18,
2012, accepted June 19, 2012.2) whether C-IMT variables, ICCAD, or their combina-
tions significantly add to the predictive accuracy of standard
models for cardiovascular risk stratification.
Methods
Participants. The design, objectives, methods, eligibility
criteria, and baseline evaluation of the IMPROVE study
were reported in the text and online material of Baldassarre
et al. (19). Briefly, 3,711 individuals (age 54 to 79 years)
with at least 3 VRFs, free from cardiovascular and cerebro-
vascular disease, were enrolled in 7 centers in Finland,
France, Italy, the Netherlands, and Sweden (details in the
Online Appendix). The measure of carotid diameter was
not available for 8 individuals, so this report refers to 3,703
subjects.
Carotid ultrasound examination. Seven identical ma-
chines (Technos, Esaote, Genoa, Italy) equipped with a 5-
to 10-MHz linear array probe were used. All machines were
calibrated with a phantom at baseline and checked after 1
year. The far walls of the left and right common carotids,
bifurcations, and internal carotid arteries were visualized at
3 scan angles (lateral, anterior, and posterior) and recorded
on S-VHS videotapes. Each segment was measured in at
least 3 different frames. ICCAD was measured in the
second centimeter of the common carotid proximal to the
bifurcation. All measurements were made in the Milan
center using dedicated software (M’Ath, Metris SRL, Ar-
genteuil, France) (20). The list of ultrasonographic variables
considered, with definitions and precision metrics, are
shown in Table 1. Anatomical locations are shown in
Online Figure 1. Spearman correlations between ultrasono-
graphic variables were all significant (all p  0.0001)
(Online Table 1).
As shown in Online Figure 1, plaques were incorporated
in IMT measurements. However, to assess the potential
incremental prognostic value of plaque, IMT variables were
also measured after excluding plaques (defined as IMTmax1.5).
he variable “presence of at least 1 plaque” was recorded.
ardiovascular events. The occurrence of CVEs (myocar-
ial infarction, sudden cardiac death, angina pectoris, isch-
mic stroke, transient ischemic attack, new diagnosis of
ntermittent claudication, heart failure, or any surgical
ntervention or revascularization of coronary or peripheral
rteries) was assessed at months 15, 30, and at the end of
ollow-up. Carotid surgical or endovascular procedures were
ot included among endpoints, as these procedures might
e directly related to the qualifying carotid ultrasound
nvestigation at study entry or during follow-up. Angina
ectoris, myocardial infarction, and ischemic stroke were
iagnosed according to European Society of Cardiology
uidelines (21,22). All events were validated by local spe-
ialists through medical records and death certificates.
opies of documents were sent to a designated specialist
U.d.F.), who was unaware of clinical history and C-IMT
ata, for adjudication.
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October 16, 2012:1489–99 Carotid Measurements and Prediction of Cardiovascular EventsEthical considerations. The study complies with the rules
of good clinical practice and with the ethical principles
established in the Declaration of Helsinki, and was ap-
proved by 7 independent ethics committees. All patients
gave written informed consent.
Statistical analysis. Quantitative variables were reported as
ean  SD. Variables with skewed distributions were
presented as median and interquartile range, and log-
transformed before analysis. Categorical variables were re-
ported as frequency and percentage. Cox models were used
to estimate crude and adjusted hazard ratios (HRs) and to
compute adjusted Kaplan-Meier survival curves. Integrated
discrimination improvement (IDI), net reclassification im-
provement (NRI), and C-statistics were used to identify the
best ultrasonographic variables for predictive purposes, and
to assess their potential to improve risk prediction based on
Framingham risk factors (FRFs) (age, sex, total cholesterol,
high-density lipoprotein cholesterol, systolic blood pressure,
hypertension, diabetes, current smoking, and antihyperten-
sive treatments) (details in the Online Appendix). We used
FRFs instead of the Framingham risk score (FRS) as this
algorithm is not specifically calibrated for a European
population.
All statistical tests were 2-sided at a level of signifi-
cance of 0.05 or 0.01, as indicated. The Bonferroni
method was applied to account for multiple comparisons.
All analyses were performed using SAS version 9.2 (SAS
Definitions of Carotid IMT Ultrasonographic VariablesTable 1 Definitions of Carotid IMT Ultrasonographic Variables
Name Definitions
1stCC-IMTmean Average of 6 mean IMT values obtained by measuring left and
length) in the first centimeter proximal to the bifurcation in
(lateral, anterior, and posterior)
1stCC-IMTmax The highest among all the maximal IMT values measured in e
6 first centimeters of the CC segments
CC-IMTmean Average of all mean IMT values obtained from left and right C
entire length (excluding the first centimeter) with sequentia
of 1-cm length, in the 3 scan angles. The total number of se
ranged from 6 to 24 according to the length of the subject’
segment, the software automatically provided the maximal
CC-IMTmax The highest of all the maximal IMT values detected in the 6–2
Bif-IMTmean Average of 6 mean IMT values obtained by measuring left and
(1-cm length) in the 3 scan angles (lateral, anterior, and po
Bif-IMTmax The highest maximal IMT value measured in the 6 Bif segmen
ICA-IMTmean Average of 6 mean IMT values obtained by measuring left and
first cm proximal to bifurcations) in the 3 scan angles (later
posterior)
ICA-IMTmax The highest maximal IMT value measured in the 6 ICA segmen
IMTmean Average of 1
stCC-IMTmean, CC-IMTmean, Bif-IMTmean, and ICA-IM
left and right carotid arteries
IMTmax Highest value out of 1
stCC-IMTmax, CC-IMTmax, Bif-IMTmax, and
of left and right carotid arteries
IMTmean-max Average of maximal IMT measured in 8 segments (1
stCC, CC,
in left and right carotid arteries)
ICCAD Average of left and right interadventitia common carotid arter
Reproducibility data between 125 intrasonographer and 32 intersonographer duplicate scans are
1stCC  first centimeter of the common carotid; Bif  bifurcation; CC  common carotid; ICA Institute, Cary, North Carolina). Reclassification statis- atics were assessed with the SAS macros published by Cook
and Ridker (23).
Results
Baseline characteristics of participants with and without CVEs
are shown in Table 2. Mean age was 64.2 years, and 47.9% of
subjects were males. A total of 514 (13.9%) participants were
free of relevant pharmacological treatments.
Follow-up and cardiovascular events. Over a median
follow-up of 36.2 months (interquartile range: 35.8 to 37.4),
215 CVEs occurred (incidence per 1,000 person-years 19.9):
125 CVEs were coronary, 73 cerebrovascular, and 17 periph-
eral. Number of subjects lost to follow-up was 238 (6.4%)
(details of CVEs and those lost to follow-up are in the Online
Appendix).
C-IMT, ICCAD, and risk of combined endpoint. All
measures of C-IMT and ICCAD were significantly associ-
ated with the risk of combined CVEs (Table 3), both before
(Model 1) and after (Model 2) adjustment for age and sex
(all p  0.0042; threshold according to Bonferroni correc-
tion for 12 comparisons). The adjusted HR for 1 SD
increase ranged from 1.27 (1stCC-IMTmax) to 1.47
(IMTmean-max) for IMT variables, and was 1.41 for ICCAD.
hese associations remained significant according to
onferroni criteria even after stratification by center and
Absolute Differences (Mean  SD) ICCs
Intra Inter Intra Inter
CC (1-cm
scan angles
0.031 0.03 0.045 0.041 0.95 0.89
f the 0.039 0.041 0.079 0.072 0.92 0.83
lized in their
movements
ts visualized
. In each
lue
0.089 0.161 0.101 0.081 0.92 0.95
egments 0.067 0.101 0.138 0.307 0.96 0.52
Bif
)
0.09 0.114 0.139 0.178 0.93 0.76
0.093 0.122 0.204 0.26 0.84 0.68
ICAs (the
erior, and
0.17 0.204 0.195 0.153 0.95 0.94
0.195 0.283 0.331 0.459 0.91 0.60
0.038 0.05 0.054 0.095 0.96 0.87
Tmax 0.164 0.227 0.239 0.238 0.95 0.89
d ICA 0.096 0.109 0.134 0.145 0.95 0.88
eters 0.037 0.037 0.031 0.023 0.99 0.99
ported. Composite variables (IMTmean, IMTmax, and IMT mean-max) refer to the whole carotid tree.
al carotid artery; ICC  intraclass correlation coefficient; IMT  intima-medial thickness.right
the 3
ach 1 o
C visua
l probe
gmen
s neck
IMT va
4 CC s
right
sterior
ts
right
al, ant
ts
Tmean,
ICA-IM
Bif, an
y diamdjustment for VRFs (Model 3). Of note, the effect of the
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negligible (Model 4).
Figure 1 shows the FRS-adjusted Kaplan-Meier inci-
dence curves after stratifying subjects into 4 groups accord-
ing to IMTmean-max and ICCAD above or below their
respective medians. The apparent additive effect shown in
this figure was confirmed when IMTmean-max and ICCAD
were mutually adjusted in a Cox model including age and
sex. HRs for 1 SD increase of IMTmean-max and ICCAD
ere 1.36 (95% confidence interval [CI]: 1.18 to 1.58, p 
.001) and 1.18 (95% CI: 1.01 to 1.38, p  0.03),
espectively. No significant interaction (p 0.63) was found
Baseline Characteristics of IMPROVE Study ParticipTable 2 Baseline Characteristics of IMPROVE S
Entire Sample
(N  3,703)
Kuopio (pooled) 1,048 (28.3)
Stockholm 532 (14.4)
Groningen 527 (14.2)
Paris 501 (13.5)
Milan 553 (14.9)
Perugia 542 (14.6)
Anthropometric variables
Male 1,774 (47.9)
Age, yrs 64.2 5.4
BMI, kg/m2 27.3 4.27
Waist/hip ratio 0.92 0.09
Diastolic blood pressure, mm Hg 82.0 9.8
Systolic blood pressure, mm Hg 142.0 18.5
Smoking habits
Current smokers 549 (14.8)
Former smokers 1,371 (37.0)
Never smokers 1,783 (48.2)
Pack-years* 18 (8–30)
Biochemical markers
Total cholesterol, mmol/l 5.49 1.13
HDL cholesterol, mmol/l 1.26 0.36
Triglycerides, mmol/l 1.3 (0.93, 1.89
LDL cholesterol, mmol/l 3.54 1.01
Uric acid, mol/l 310 (263–360)
hs-CRP, mg/l 2.06 (0.96–3.80
Blood glucose, mmol/l 5.92 1.64
Creatinine, mol/l 79 (68–91)
Personal history
Hypercholesterolemia 2,581 (69.7)
Hypertriglyceridemia 954 (25.8)
Low HDL 488 (13.2)
Hypertension 2,552 (68.9)
Diabetes 913 (24.7)
Framingham risk score 22.6 (14.3–34.4
5% 43 (1.20)
5, 10% 354 (9.6)
10, 15% 570 (15.4)
15, 20% 564 (15.2)
20% 2,021 (54.6)etween IMTmean-max and ICCAD.MTmean-max, ICCAD, and risk of coronary and cerebro-
vascular endpoints. The HRs of coronary and cerebrovas-
cular endpoints for selected IMT variables and ICCAD, are
shown in Table 4. Age- and sex-adjusted standardized HRs
ranged from 1.19 to 2.51 and were generally higher for
cerebrovascular endpoints. No significant interaction be-
tween ultrasonographic variables and type of vascular event
was found, with p values of Model 3 ranging from 0.237 to
0.900.
Online Table 2 shows the same analysis as in Table 4, but
restricted to “hard clinical events.” Although no significant
association with hard coronary events was detected, most of
With and Without Vascular EventsParticipants With and Without Vascular Events
Without Event
(n  3488)
With Event
(n  215) p Value
972 (27.9) 76 (35.3)
508 (14.6) 24 (11.2)
478 (13.7) 49 (22.8) 0.0001
476 (13.6) 25 (11.6)
533 (15.3) 20 (9.30)
521 (14.9) 21 (9.77)
1,641 (47.0) 133 (61.9) 0.0001
64.1 5.40 65.4 5.84 0.0012
27.2 4.25 28.0 4.56 0.023
0.92 0.09 0.94 0.08 0.0001
81.9 9.75 82.8 10.4 0.32
141.7 18.3 145.8 20.5 0.010
501 (14.4) 47 (21.9)
1,272 (36.5) 96 (44.7) 0.0001
1,712 (49.1) 71 (33.0)
18 (8–30) 21 (11–30) 0.06
5.49 1.13 5.50 1.05 0.75
1.27 0.36 1.18 0.30 0.0007
1.3 (0.92, 1.87) 1.48 (1.09, 2.17) 0.0001
3.55 1.01 3.53 0.94 0.75
309 (263–359) 329 (274–390) 0.0003
2.05 (0.95–3.75) 2.30 (1.22–4.63) 0.012
5.91 1.65 6.05 1.42 0.013
79 (68–90) 84 (74–97) 0.0001
2,450 (70.2) 131 (60.9) 0.004
893 (25.6) 61 (28.4) 0.37
449 (12.9) 39 (18.1) 0.027
2,391 (68.5) 161 (74.9) 0.053
846 (24.3) 67 (31.2) 0.023
22.2 (14.2–33.8) 30.8 (19.1–47.6) 0.0001
42 (1.2) 1 (0.5)
347 (9.9) 7 (3.3)
546 (15.7) 24 (11.2)
539 (15.5) 25 (11.6)
1,875 (53.8) 146 (67.9) 0.0001
Continued on next pageantstudy
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criteria, even after adjustment for age and sex (Models 1 and 2). In
Model 3, only ICCAD remained significantly associated
with ischemic stroke after Bonferroni correction.
Performance of several measures of subclinical athero-
sclerosis as predictors of subsequent CVEs. IDI values in
Table 5 show that IMTmean and IMTmean-max, and their
ombination with ICCAD, performed better than CC-IMTmean
(the IMT variable most widely used in ultrasonographic
studies). The NRI using these variables ranged from 10.7%
(IMTmean) to 20.1% (ICCAD  IMTmax). When the
analysis was repeated considering coronary or cerebrovascu-
lar endpoints, composite IMT variables performed better
than CC-IMTmean in the reclassification of cerebrovascular
events, but not in reclassification of coronary events. Re-
ContinuedTable 2 Continued
Entire Sample
(N  3,703)
Family history
CHD 2,315 (62.5) 2
CVD 1,322 (35.7) 1
PVD 443 (12.0)
Therapies
Statins 1,483 (40.0)
Fibrates 284 (7.7)
Fish oil 125 (3.4)
Other lipid-lowering drugs 23 (0.62)
Beta blockers 878 (23.7)
Calcium antagonists 603 (16.3)
ACE inhibitors 722 (19.5)
Alpha-2 inhibitors 45 (1.22)
Sartans 562 (15.2)
Diuretics 857 (23.1)
Antiplatelet agents 618 (16.7)
Insulin 141 (3.81)
Estrogen supplement 226 (11.7)
Ultrasonographic variables, mm
CC-IMTmean 0.71 (0.65–0.80)
1stCC-IMTmean 0.76 (0.69–0.87)
Bif-IMTmean 1.06 (0.85–1.34)
ICA-IMTmean 0.75 (0.64–1.00)
CC-IMTmax 1.07 (0.96–1.30)
1stCC-IMTmax 1.08 (0.96–1.30)
Bif-IMTmax 1.67 (1.30–2.22)
ICA-IMTmax 1.17 (0.93–1.76)
IMTmean 0.85 (0.74–1.00)
IMTmax 1.85 (1.39–2.50)
IMTmean-max 1.34 (1.12–1.65)
Plaque†, No.(%) 2,576 (69.5)
ICCAD 7.74 (7.22–8.32)
Values are n (%), mean  SD, or median (interquartile range). p Val
convert biochemical markers in mg/dl, divide values of total and HD
of uric acid by 59.48, values of blood glucose by 0.0556122, and
calculated in 151 patients because of missing data in 1 of the v
†Plaque  presence of at least 1 plaque.
ACE  angiotensin-converting enzyme; BMI  body mass index
high-sensitivity C-reactive protein; LDL  low-density lipoprotein; othegardless of the type of endpoint considered, models with the icombination ICCAD  IMTmean or IMTmean-max always
performed significantly better than CC-IMTmean.
Table 6 shows that in IDI analysis, the variable “Presence of
t least 1 plaque,” defined as IMTmax 1.5, performed signif-
icantly better than IMTmean only when the latter was measured
n plaque-free areas; otherwise, the predictive value of the
laque presence alone was always significantly worse.
ncremental value of C-IMT with respect to FRFs. The
ombination of IMT variables or ICCAD with FRFs added
ittle to the overall risk discrimination based on FRFs alone
n receiver-operating characteristic (ROC) analyses (all p
alues0.05), but performed significantly better than FRFs
lone in reclassification analyses (Table 7). In most cases,
DI values reached statistical significance even after Bon-
erroni correction. The combination of FRFs plus compos-
Without Event
(n  3488)
With Event
(n  215) p Value
62.1) 146 (67.9) 0.062
35.6) 81 (37.7) 0.53
11.8) 29 (13.5) 0.42
8 (40.4) 75 (34.9) 0.11
4 (7.86) 12 (5.58) 0.23
0 (3.44) 5 (2.33) 0.38
1 (0.60) 2 (0.93) 0.55
5 (23.4) 64 (29.8) 0.03
8 (16.0) 45 (20.9) 0.06
3 (19.6) 39 (18.1) 0.60
2 (1.20) 3 (1.40) 0.80
9 (15.2) 33 (15.3) 0.94
4 (23.1) 53 (24.7) 0.59
1 (16.1) 57 (26.5) 0.0001
1 (3.76) 10 (4.65) 0.51
0 (6.31) 6 (2.79) 0.04
1 (0.65–0.79) 0.77 (0.69–0.88) 0.0001
6 (0.69–0.86) 0.81 (0.73–0.96) 0.0001
5 (0.84–1.33) 1.17 (0.94–1.55) 0.0001
5 (0.63–0.98) 0.89 (0.68–1.23) 0.0001
6 (0.95–1.30) 1.15 (1.03–1.48) 0.0001
8 (0.96–1.27) 1.18 (1.01–1.48) 0.0001
7 (1.30–2.22) 1.93 (1.45–2.59) 0.0001
6 (0.92–1.74) 1.48 (1.02–2.20) 0.0001
4 (0.74–0.99) 0.95 (0.81–1.13) 0.0001
5 (1.39–2.48) 2.31 (1.65–2.89) 0.0001
3 (1.12–1.63) 1.52 (1.28–1.89) 0.0001
7 (68.7) 179 (83.2) 0.0001
2 (7.20–8.30) 8.13 (7.53–8.66) 0.0001
re calculated by Wilcoxon test or by chi-square as appropriate. To
sterol by 0.0259016, values of triglycerides by 0.0113815, values
of creatinine by 87.777778. The Framingham risk score was not
s included in the algorithm. *Calculated excluding never smokers.
coronary heart disease; HDL  high-density lipoprotein; hs-CRP 
viations as in Table 1.,165 (
,240 (
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increased NRI from 12.1% to 13.0%. The use of the FRS in
place of FRFs in reclassification analyses provided similar
results (data not shown).
Table 8 shows the estimated 10-year CVE risk categories
according to FRFs before and after adding ICCAD and
IMTmean-max. The overall NRI was 12% (p  0.003), and
35.9% of subjects at intermediate risk were reclassified.
HRs (95% CI) of Combined Vascular Endpoints pfor Ultrasonographic Continuous (Log-TransformTable 3 HRs (95% CI) of Combined Va culafor Ultrasonographic Continuous (Lo
Model 1 Mo
CC-IMTmean 1.44 (1.29–1.61) 1.33 (1
1stCC-IMTmean 1.40 (1.25–1.57) 1.30 (1
Bif-IMTmean 1.40 (1.23–1.59) 1.28 (1
ICA-IMTmean 1.43 (1.28–1.61) 1.34 (1
CC-IMTmax 1.37 (1.23–1.53) 1.28 (1
1stCC-IMTmax 1.35 (1.21–1.51) 1.27 (1
Bif-IMTmax 1.39 (1.22–1.59) 1.29 (1
ICA-IMTmax 1.46 (1.29–1.65) 1.36 (1
IMTmean 1.58 (1.40–1.78) 1.45 (1
IMTmax 1.49 (1.31–1.71) 1.38 (1
IMTmean-max 1.59 (1.40–1.81) 1.47 (1
ICCAD 1.54 (1.36–1.74) 1.41 (1
Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: adj
history of diabetes and of hypertension, family history of diabetes, fam
Model 3 plus pharmacological treatments (statins, beta-blockers, AC
according to Bonferroni correction for 12 comparisons. This thresh
independent (for example, IMTmean-max and IMTmean) in order to be co
CI  confidence interval; HDL-C  high-density lipoprotein cholest
vascular risk factor; other abbreviations as in Tables 1 and 2.
Figure 1 FRS-Adjusted Kaplan-Meier Incidence Curves
The study population was stratified according to IMTmean-max and ICCAD values above or b
for the mean value of FRS (22.6%). FRS  Framingham Risk score; ICCAD  interadventiSex differences. Men and women differed in mean values for
many baseline variables (data not shown), but no significant
interactions with sex were found in any of the analyses presented.
Discussion
In this study of Europeans with at least 3 VRFs, but no
overt cardiovascular or cerebrovascular disease, we found
SD Increaseariablespoints p r 1 SD Increase
nsformed) Variables
Model 3 Model 4
50) 1.30 (1.14–1.49) 1.31 (1.14–1.49)
47) 1.26 (1.10–1.44) 1.26 (1.10–1.44)
47) 1.25 (1.08–1.45) 1.24 (1.08–1.44)
51) 1.26 (1.10–1.44) 1.27 (1.11–1.44)
44) 1.27 (1.12–1.44) 1.27 (1.12–1.44)
43) 1.22 (1.08–1.39) 1.22 (1.07–1.38)
47) 1.27 (1.09–1.47) 1.26 (1.08–1.46)
55) 1.30 (1.13–1.49) 1.30 (1.14–1.50)
66) 1.39 (1.21–1.61) 1.39 (1.21–1.61)
58) 1.35 (1.16–1.57) 1.35 (1.16–1.57)
68) 1.43 (1.23–1.65) 1.43 (1.23–1.65)
62) 1.28 (1.09–1.50) 1.27 (1.08–1.50)
r age, sex, and VRFs (LDL-C, HDL-C, systolic blood pressure, personal
ory of hypertension, pack-years), and stratified by center; Model 4 as
itors, diuretics, and calcium antagonists). All p  0.0042; threshold
selected even if some of the IMT variables were not statistically
tive.
 hazard ratio; LDL-C  low-density lipoprotein cholesterol; VRF 
eir respective medians (1.34 mm and 7.74 mm, respectively). Curves were computed
mon carotid artery diameter; IMT  mean–maximum intima-media thickness.er 1ed) Vr End
g-Tra
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October 16, 2012:1489–99 Carotid Measurements and Prediction of Cardiovascular Eventsthat increased IMTs and ICCAD enlargement are inde-
pendent predictors of CVEs. Importantly, the HRs of these
ultrasonographic variables remained significant after adjust-
ment for pharmacological treatment. Thus, even in the
presence of effective antiatherosclerotic treatments, IMT
and ICCAD provide additional information that can be
used as an adjunct to FRFs to refine the estimate of
cardiovascular risk. The HRs found in our study are in line
with those reported in the CHS (Cardiovascular Health
Study) (24), ARIC (Atherosclerosis Risk in Communities)
HRs (95% CI) of Coronary and Cerebrovascularfor Ultrasonographic Continuous (Log-StandardizTable 4 HRs (95% CI) of Coronary and Ce efor Ultrasonographic Continuous (Lo
Model
Coronary endpoints (n  125)
CC-IMTmean 1.40 (1.22–1
CC-IMTmax 1.30 (1.12–1
IMTmean 1.51 (1.29–1
IMTmax 1.42 (1.20–1
IMTmean-max 1.52 (1.29–1
ICCAD 1.48 (1.26–1
Cerebrovascular endpoints (n  73)
CC-IMTmean 1.46 (1.21–1
CC-IMTmax 1.40 (1.16–1
IMTmean 1.70 (1.39–2
IMTmax 1.65 (1.31–2
IMTmean-max 1.74 (1.41–2
ICCAD 1.63 (1.33–2
Model 1: unadjusted; Model 2: adjusted for age and sex; Model 3: a
pressure, personal history of diabetes and of hypertension, family hist
treatments (statins, beta-blockers, ACE inhibitors, diuretics and calcium
*p  0.0083: threshold according to Bonferroni correction for 6 comp
not statistically independent (e.g., IMTmean-max and IMTmean) in order
Abbreviations as in Tables 1 and 3.
Reclassification Statistics for Ultrasonographic Variables as CompBased on CC-IMTmean Only in Risk Models With Combined, CoronarTable 5 Reclassification Sta istics fo Ultrasonographic VariabBased on CC-IMTmean Only in Risk Models With Combi
NRI (%) (95% CI)
New Model Combined Endpoints
Cerebrovascular
Endpoints Coronary Endp
1stCC-IMTmean 0.1 (7.9 to 7.6) 1.4 (12.4 to 15.2) 2.1 (9.6 to 1
Bif-IMTmean 2.0 (14.3 to 10.3) 3.1 (21.4 to 15.1) 6.9 (22.5 to
ICA-IMTmean 0.7 (13.1 to 11.8) 16.6 (3.9 to 37.1) 3.2 (19.9 to
CC-IMTmax 3.9 (11.5 to 3.6) 2.1 (8.5 to 12.6) 6.6 (16.9 to
1stCC-IMTmax 2.4 (11.6 to 6.7) 3.4 (17.2 to 10.4) 0.9 (12.5 to
Bif-IMTmax 1.5 (13.6 to 10.5) 0.8 (20.3 to 18.7) 5.7 (21.7 to
ICA-IMTmax 2.9 (16.1 to 10.2) 15.1 (4.6 to 34.8) 0.1 (17.2 to
ICCAD 4.9 (7.7 to 17.5) 3.3 (13.6 to 20.2) 1.7 (13.7 to
IMTmax 9.2 (3.0 to 21.3) 6.8 (12.3 to 25.9) 0.9 (14.7 to
IMTmean 10.7 (0.6 to 22.1) 8.7 (8.6 to 26.1) 3.3 (11.1 to
IMTmean-max 11.6 (0.1 to 23.1) 11.6 (5.7 to 29.0) 6.0 (9.7 to 2
ICCAD  CC-IMTmean 11.0 (1.6 to 20.4) 11.5 (3.4 to 26.4) 5.1 (8.3 to 1
ICCAD  IMTmax 20.1 (7.1 to 33.1)* 19.8 (0.1 to 39.7) 6.0 (9.7 to 2
ICCAD  IMTmean 17.8 (6.1 to 29.5)* 15.1 (3.5 to 33.8) 9.9 (4.8 to 2
ICCAD  IMTmean-max 19.9 (7.5 to 32.3)* 19.4 (1.2 to 37.7) 9.8 (5.1 to 2
When NRI and/or IDI values are positive with a p  0.01 (in bold), then the new model (first colum
n bold. *p 0.0033: threshold according to Bonferroni correction for 15 comparisons. This thresho
and IMTmean) in order to be conservative.
IDI  integrated discrimination improvement; NRI  net reclassification improvement; other abbrevia(25,26), and Rotterdam (27) studies, despite considerable
differences in ultrasound protocols and population charac-
teristics.
Are composite IMT measurements better predictors than
CC-IMT? Consistently with other studies (4,24–26,28,29), we
found that the 11 IMT variables considered were all
significantly associated with combined CVEs. However,
using reclassification analyses, we showed that there is a
significant advantage in using IMTmean or IMTmean-max
over CC-IMT—but this is true only when combined CVEs
oints per 1 SD Increaseariabl sscular Endpoints p r 1 SD Increase
andardized) Variables
Model 2 Model 3
1.27 (1.09–1.49)* 1.25 (1.05–1.49)
1.19 (1.02–1.39) 1.17 (0.99–1.39)
1.35 (1.14–1.59)* 1.26 (1.04–1.53)
1.27 (1.07–1.52)* 1.21 (1.00–1.47)
1.36 (1.14–1.61)* 1.28 (1.05–1.55)
1.30 (1.09–1.55)* 1.19 (0.96–1.46)
1.38 (1.13–1.69)* 1.36 (1.09–1.71)*
1.34 (1.10–1.62)* 1.34 (1.09–1.65)*
1.63 (1.32–2.03)* 1.58 (1.25–2.01)*
1.56 (1.23–1.98)* 1.58 (1.22–2.04)*
1.67 (1.33–2.09)* 1.66 (1.30–2.13)*
1.63 (1.29–2.06)* 1.53 (1.17–2.01)*
for age, sex, and vascular risk factors (LDL-C, HDL-C, systolic blood
iabetes, family history of hypertension, pack-years), pharmacological
onists) and stratified by center. Hazard ratios with p 0.05 are in bold.
. This threshold was selected even if some of the IMT variables were
nservative.
With ClassificationCerebrovascular EndpointsComp red Wi h Classification
Coronary, or Cerebrovascular Endpoints
IDI (99% CI)
Combined
Endpoints
Cerebrovascular
Endpoints
Coronary
Endpoints
0.004 (0.013 to 0.005) 0.004 (0.011 to 0.003) 0.003 (0.011 to 0.005)
0.009 (0.022 to 0.005) 0.004 (0.014 to 0.006) 0.009 (0.02 to 0.002)
0.003 (0.018 to 0.011) 0.013 (0.0003 to 0.027) 0.009 (0.021 to 0.002)
0.006 (0.013 to 0.003) 0.002 (0.007 to 0.004) 0.008 (0.013 to 0.003)
0.009 (0.019 to 0.001) 0.006 (0.014 to 0.002) 0.006 (0.015 to 0.002)
0.010 (0.024 to 0.003) 0.001 (0.011 to 0.011) 0.012 (0.023 to 0.001)
0.004 (0.018 to 0.011) 0.008 (0.005 to 0.021) 0.007 (0.019 to 0.005)
0.008 (0.005 to 0.02) 0.007 (0.003 to 0.018) 0.0002 (0.01 to 0.01)
0.015 (0.003 to 0.027)* 0.009 (0.003 to 0.020) 0.005 (0.016 to 0.006)
0.0004 (0.013 to 0.014) 0.015 (0.005 to 0.025)* 0.005 (0.005 to 0.014)
0.014 (0.002 to 0.026) 0.018 (0.007 to 0.028)* 0.003 (0.007 to 0.012)
0.015 (0.006 to 0.023)* 0.010 (0.002 to 0.018)* 0.006 (0.0004 to 0.012)
0.023 (0.009 to 0.036)* 0.022 (0.010 to 0.034)* 0.007 (0.003 to 0.018)
0.028 (0.016 to 0.039)* 0.023 (0.012 to 0.034)* 0.011 (0.002 to 0.021)
0.028 (0.016 to 0.04)* 0.026 (0.015 to 0.037)* 0.010 (0.001 to 0.020)
tter than the model that includes CC-IMTmean only and vice versa. Hazard ratios with p  0.05 are
selected even if some of IMT variables were not statistically independent (for example, IMTmean-maxEndped) Vbrova
g-St
1
.62)*
.50)*
.76)*
.68)*
.78)*
.73)*
.75)*
.68)*
.08)*
.07)*
.15)*
.00)*
djusted
ory of d
antag
arisonsaredy, orles as
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oints
3.8)
8.6)
13.5)
3.7)
14.3)
10.4)
17.4)
17.1)
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17.6)
1.7)
8.4)
1.7)
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Carotid Measurements and Prediction of Cardiovascular Events October 16, 2012:1489–99or cerebrovascular events are considered. In line with the
ARIC study (30), CC-IMT was as good as composite IMT
variables in improving the prediction of coronary events
(Tables 4 and 5). A possible explanation is that the presence
of atherosclerosis in the bifurcation or in the internal carotid
may actually cause cerebrovascular events, whereas it is
merely a marker of coronary atherosclerosis. Interestingly, in
reclassification analyses, composite IMTs that incorporate
plaques in their measurement performed significantly better
than the presence of plaque.
ICCAD as predictor of vascular events. Compared with
CC-IMT alone, the best reclassification was obtained by
combining IMTmean-max and ICCAD. The NRI using this
combination was 19% for combined and cerebrovascular
events and 9.8% for coronary events.
Although prospective studies (31) suggest a role for IMT
as a predictor of myocardial infarction and stroke, evidence
on the predictive capacities of ICCAD is sparse. Two
studies reported that IMT is a predictor of CVEs indepen-
dently of lumen diameter (32,33). Only 1 large population
study (9) showed that even after adjusting for IMT and
VRFs, right ICCAD was significantly associated with
Reclassification Statistics Comparing Ultrasonographic Variables a(Presence of at Le st 1 Plaque) in Risk Models With Comb ned VTable 6 Reclassification Statistic Comparing Ultrasonographic(Presence of at Least 1 Plaque) in Risk Models With C
New Model Reference Model N
Plaque IMTmean measured in plaque-free areas 0.8
Plaque IMTmean measured in all areas (including plaque) 8.5
Plaque IMTmax 7.9
Plaque IMTmean-max 10.4
When NRI and/or IDI values are positive with a p  0.05 and p  0.01, respectively then the new
Abbreviations as in Tables 1, 3, and 5.
Reclassification Statistics for the Added Value of UltrasonographicCarotid Segme ts, and Carotid Outcomes s Compared With RefTable 7 R classification S atistics for the Added Value of UltraCarotid Segments, and Carotid Outcomes as Compare
New Model
AUC
(New Model)
Total,
n
Reclassified,
n
Correc
Reclassifie
FRFs  CC-IMTmean 0.687 3,381 622 380 (
FRFs  1stCC-IMTmean 0.690 3,384 548 331 (
FRFs  Bif-IMTmean 0.686 3,364 568 318 (
FRFs  ICA-IMTmean 0.699 3,356 675 405 (
FRFs  CC-IMTmax 0.686 3,381 539 335 (
FRFs  1stCC-IMTmax 0.690 3,384 503 306 (
FRFs  Bif-IMTmax 0.687 3,364 611 363 (
FRFs  ICA-IMTmax 0.704 3,356 788 483 (
FRFs  IMTmax 0.697 3,384 787 476 (
FRFs  IMTmean 0.702 3,384 857 528 (
FRFs  IMTmean-max 0.708 3,384 915 568 (
FRFs  ICCAD 0.692 3,384 663 397 (
FRFs  ICCAD  IMTmax 0.705 3,384 924 572 (
FRFs ICCAD  IMTmean 0.706 3,384 935 601 (
FRFs  ICCAD  IMTmean-max 0.711 3,384 986 637 (
FRFs  ICCAD  IMTmean-max
 Plaque
0.710 3,384 1,010 647 (
AUC of reference model 0.674. When NRI and/or IDI values are positive with a p 0.05 and p
versa. Plaque  presence of at least 1 plaque, defined as IMTmax 1.5 mm.
AUC  area under the curve; FRF  Framingham risk factor; other abbreviations as in Tables 1, 3, andincident cardiac events. We also found the highest esti-
mated cumulative incidence of events in subjects having
both diameter enlargement and increased IMT. Despite
this, Eigenbrodt et al. (9) reported that on the basis of ROC
analyses, carotid diameter measures added little to overall
risk discrimination, especially after VRF adjustment (9).
Our own ROC curve analysis (Table 7) agrees with this
finding, but using IDI statistics, the inclusion of ICCAD
into a model based on FRFs significantly added to the
overall risk discrimination.
C-IMTs and ICCAD are independent biomarkers of
atherosclerosis. The fact that C-IMTs and ICCAD pre-
dict the risk of CVEs independently of each other, together
with the finding that these variables are associated with
different VRFs (14,34), suggests that IMTs and ICCAD
represent independent arterial responses to different patho-
physiological mechanisms. C-IMT assesses atherosclerosis,
depending on whether atherosclerotic plaques are incorpo-
rated in IMT measurements or not. When plaques are
incorporated, as in our case, IMT reflects atherosclerosis
(27,35). Arterial diameter enlargement reflects at least 2
processes. The first is vascular remodeling in response to the
laque Informationr Endpointsi bles and Plaque Information
ined Vascular Endpoints
% CI) p Value IDI (99% CI) p Value
.6 to 11.2) 0.88 0.017 (0.004 to 0.03) 0.001
9.0 to 1.9) 0.11 0.029 (0.041 to0.017) 0.001
8.0 to 2.2) 0.13 0.014 (0.023 to0.006) 0.0001
0.5 to0.3) 0.04 0.028 (0.04 to0.017) 0.001
l is better than the reference model and vice versa.
ables in Risk Models With Combined Endpoints,e Model Based on FRFs Onlygraph c Variables in isk Models With Combined Endpoints,
h a Reference Model Based on FRFs Only
) NRI % (95% CI) p Value IDI (99% CI) p Value
p Bonferroni
Holm
4.8 (1.5 to 11.2) 0.14 0.009 (0.002 to 0.016) 0.01 0.05
5.2 (1.0 to 11.5) 0.10 0.007 (0.001 to 0.014) 0.01 0.06
2.7 (2.7 to 8) 0.33 0.008 (0.002 to 0.013) 0.001 0.05
6.4 (1.0 to 13.7) 0.09 0.011 (0.004 to 0.019) 0.001 0.01
8.2 (2 to 14.4) 0.01 0.008 (0.001 to 0.014) 0.01 0.05
7.6 (1.8 to 13.4) 0.01 0.006 (0.001 to 0.012) 0.01 0.13
4.1 (1.8 to 10.1) 0.17 0.008 (0.002 to 0.015) 0.001 0.05
9.3 (1.6 to 16.9) 0.02 0.013 (0.005 to 0.021) 0.0001 0.01
6.2 (0.8 to 13.1) 0.08 0.013 (0.006 to 0.02) 0.0001 0.001
11.3 (3.6 to 19.1) 0.01 0.016 (0.008 to 0.025) 0.0001 0.0001
10.5 (2.4 to 18.6) 0.01 0.018 (0.009 to 0.028) 0.0001 0.0001
6.7 (0 to 13.3) 0.05 0.010 (0.003 to 0.018) 0.001 0.05
5.9 (1.9 to 13.6) 0.14 0.020 (0.01 to 0.029) 0.0001 0.0001
11.4 (3.8 to 19) 0.01 0.021 (0.011 to 0.031) 0.0001 0.0001
12.1 (4.0 to 20.1) 0.01 0.023 (0.013 to 0.033) 0.0001 0.0001
13.0 (4.8 to 21.2) 0.01 0.023 (0.013 to 0.034) 0.0001 0.0001
respectively, then the new model (first column) is better than the reference model (FRFs) and vicend PsculaVar
omb
RI (95
% (9
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% (2Varierencso o
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October 16, 2012:1489–99 Carotid Measurements and Prediction of Cardiovascular Eventsgrowth of local atherosclerotic plaques (36). The second, as
measured in our study, is independent of the presence of
focal atherosclerosis (being measured in plaque-free areas);
this occurs as a compensatory response to VRFs (13,14) and
associates fairly well with the coronary artery disease status
(17). On this basis, it can be concluded that IMTs and
ICCAD provide additional information on atherosclerotic
burden, thus supporting the concept of their potential
usefulness as independent biomarkers of this multifactorial
disease. Our observation that individuals with an average
FRS have a 6.5% risk of developing a first CVE over 3 years
if their IMTmean-max and ICCAD are high, versus a 3.4%
isk if these variables are low (Fig. 1), supports this concept.
-IMTs, plaque, and ICCAD add predictive value to
RFs. It is also important to know whether C-IMT and/or
CCAD provide prognostic information for individuals over
nd above that provided by FRFs: the fact that these
ariables are significant and independent predictors of
VEs does not necessarily mean they will be useful in the
linic. This may be 1 reason for the reluctance of the
edical community to adopt C-IMT as a clinical tool (18).
ost of the authors using the ROC metric to address this
opic (3–9) have concluded that the magnitude of any
mprovement is insufficient to change current clinical and
ublic health efforts to reduce the burden of vascular
iseases (3,6–8). Our own data based on ROC analyses are
n line with such statements, as the addition of IMT and
CCAD to the risk models built on FRFs had marginal,
onsignificant effects on C-statistics (Table 7). However,
he C-statistic is insensitive to small changes in predictive
ccuracy, and even well-established VRFs may be discarded
s nonsignificant in some circumstances (37,38). Conse-
uently, there is general agreement that newer methods
uch as reclassification statistics (IDI and NRI) must be
pplied (37,39). To the best of our knowledge, only 4
tudies have so far used reclassification analyses to evaluate
hether ultrasound measures add prognostic information
ver and above traditional VRFs (10,11,30,40). The first
Risk Reclassification Comparing the Extrapolated 10-Year Risk AcBefore and After Adding ICCAD and IMTmean-max in the Prediction oTable 8 Risk Reclassification Comparing th Extrapolated 10-YBefore and After Adding ICCAD and IMTmean-max in the
10-Year Risk Categori
10-Year Risk Categories for FRFs <10%
10%*
n  680 (20%) 571 (84%)
Observed risk (95% CI) 8 (4.3–12.9)
10%–20%*
n  1,697 (50%) 364 (21.4%)
Observed risk (95% CI) 7.7 (3.3–13.9)
20%*
n  1,007 (30%) 2 (0.2%)
Observed risk (95% CI) NA
NRI: 12.1%; p  0.003
*To be noticed, these categories differ from those predicted by the Framingham risk score (see T
NA  not applicable; other abbreviations as in Tables 1, 3, 5, and 7.10) concluded that, in subjects from the general population, sodels that included C-IMT do not consistently improve
ndividual risk stratification over those including only tra-
itional VRFs. The second and the third (11,30), using data
rom the ARIC cohort, showed that compared with a model
hat includes FRFs only, the model including FRFs plus
-IMT plus information on the presence of carotid plaques
rovided a modest improvement in the area under the curve
nd a significant NRI. The last study (40) showed that the
ddition of C-IMT to FRFs significantly improved risk
lassification in women, but not in men. Our results show
hat substantial improvements over FRFs alone can be
btained when IMT variables are used, especially when
ombined with ICCAD. Therefore, our findings provide
ew evidence to support the use of IMT variables and
CCAD, in addition to VRFs, for cardiovascular risk
tratification in clinical practice, with a NRI of 12.1%. The
ifference from the conclusions of the previous studies
10,11) may be due to the characteristics of the IMPROVE
ubjects, who were chosen to have 3 VRFs instead of the
ower-risk general population, and the use of composite
MT variables instead of only CC-IMT. Clearly, the
ndividual assessment of composite IMT variables and
CCAD is time consuming compared with CC-IMT as-
essment alone (15 to 20 vs. 8 to 10 min). However, we
elieve that the benefits provided by a better risk classifica-
ion may easily offset the additional costs.
We have shown that, focusing on the intermediate (10%
o 20%) risk category, which represents the real gray
ecision area for many clinicians, the addition of ICCAD
nd IMTmean-max to a model based on FRFs allows, on
verage, the reclassification of 14.5% of subjects in the
igh-risk category (Table 8). Improving the predictability
or this group would have significant clinical implications,
ecause it means shifting subjects with the highest chance of
eveloping a CVE to the risk category qualified for phar-
acological treatment. The cost of such strategy can be
oughly estimated from the number needed to screen to
revent 1 CVE. Table 8 also shows that, of the 1,697
ng to FRFsbined Va cular Eventsisk According to FRF
iction of Combined Vascular Events
FRFs Plus ICCAD Plus IMTmean-max
%–20% >20% Reclassified, n (%)
16%) 0 (0%) 109 (16.0%)
2–23.3) NA
64.1%) 246 (14.5%) 610 (35.9%)
8.5–16.3) 40.6 (26.8–57.4)
26.3%) 740 (73.5%) 267 (26.5%)
12.4–33.6) 39.7 (31.5–48.9)
due to a recalibration of the risk estimation in our cohort.cordif Comear R
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ical treatment, and in this group, the extrapolated 10-year
incidence was 40.6% (100 events). Thus, assuming a treat-
ment efficacy of 20% to 30% (41), from 20 to 30 events
could be prevented, yielding a needed to screen ranging
from 57 to 85 (i.e., 1,697/30 and 1,697/20). It has to be
noticed that 26.3% of the high-risk subjects were down-
graded to a lower-risk category, but this does not imply that
these subjects should lose their qualification for pharmaco-
logical treatments. We believe, in fact, that the use of IMT
for cardiovascular risk reclassification should be applied only
to patients at intermediate risk.
Strengths and limitations. The IMPROVE study has
several strengths. It examined a large number of ultrasono-
graphic variables, which allowed us to identify the most
informative segment and/or the best IMT summary mea-
sure to be used for predictive purposes. The study was
conducted across 5 European countries. Methods of carotid
image acquisition and measurement of C-IMT were stan-
dardized across centers (all sonographers were trained and
certified, and all scans were analyzed blindly in the same
reading center). With follow-up data obtained on 93.7% of
patients, our results were minimally affected by “loss to
follow-up” bias. Finally, the analyses were adjusted for many
potential confounders not considered in previous studies, for
example, pharmacological treatments.
There are also potential limitations. The findings can
only be extrapolated cautiously to the general European
population or to patients with fewer than 3 VRFs. However,
the HRs we observed are similar to those reported in other
large population studies (24–27). Also, it remains possible
that systematic differences existed between recruiting cen-
ters (19). Finally, the low number of CVEs will have
constrained the precision of estimates in the subgroups
(coronary events and cerebrovascular events).
Conclusions
We conclude that C-IMT and ICCAD are independent
predictors of CVEs in European high-risk individuals; these
markers contribute significant incremental prediction be-
yond FRFs alone. A risk stratification strategy based on
C-IMT and ICCAD as an adjunct to FRFs would seem to
be a rational approach to the prevention of cardiovascular
disease.
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